{"organizations": [], "uuid": "a6c1071c64dade226c1a1f63eefc8ac1ba18c4de", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-johnson-johnsons-unit-actelion-sub/brief-johnson-johnsons-unit-actelion-submits-supplemental-new-drug-application-to-u-s-fda-seeking-approval-of-opsumit-idUSASC09Y85", "country": "US", "domain_rank": 408, "title": "BRIEF-Johnson & Johnson's Unit Actelion Submits Supplemental New Drug Application To U.S. FDA Seeking Approval Of Opsumit", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-30T16:17:00.000+03:00", "replies_count": 0, "uuid": "a6c1071c64dade226c1a1f63eefc8ac1ba18c4de"}, "author": "", "url": "https://www.reuters.com/article/brief-johnson-johnsons-unit-actelion-sub/brief-johnson-johnsons-unit-actelion-submits-supplemental-new-drug-application-to-u-s-fda-seeking-approval-of-opsumit-idUSASC09Y85", "ord_in_thread": 0, "title": "BRIEF-Johnson & Johnson's Unit Actelion Submits Supplemental New Drug Application To U.S. FDA Seeking Approval Of Opsumit", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-johnson & johnson", "sentiment": "negative"}, {"name": "fda seeking approval of opsumit  johnson & johnson", "sentiment": "neutral"}, {"name": "roval of opsumit reuters staff", "sentiment": "none"}, {"name": "min read  johnson & johnson", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "actelion", "sentiment": "none"}, {"name": "actelion pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30, 2018 / 1:20 PM / Updated 17 minutes ago BRIEF-Johnson & Johnson's Unit Actelion Submits Supplemental New Drug Application To U.S. FDA Seeking Approval Of Opsumit Reuters Staff 1 Min Read\n Johnson & Johnson:\n* ACTELION SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FDA SEEKING APPROVAL OF OPSUMITÂ® (MACITENTAN) FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)\n* ACTELION PHARMACEUTICALS SAYS SUBMITS SUPPLEMENTAL NDA TO FDA FOR APPROVAL OF OPSUMIT (MACITENTAN) FOR TREATING CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-30T16:17:00.000+03:00", "crawled": "2018-04-30T16:23:44.005+03:00", "highlightTitle": ""}